Replimune Group Inc (REPL)

NASD · Healthcare · Biotechnology · USA

Replimune Group Inc is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.

Replimune Group is a clinical-stage biotechnology company developing oncolytic immunotherapy candidates designed to activate the immune system against cancer. Its proprietary RPx platform, based on an engineered herpes simplex virus backbone, selectively kills tumors and triggers systemic anti-tumor immune responses. Lead candidates RP1 and RP2 are in clinical development for melanoma and other skin cancers.

From its FY2026 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Replimune Group Inc stock.

Our verdict on REPL

Not valued: We cannot value this company yet.

ETFs with the most weight in REPL

17 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than REPL in Biotechnology

129 more in this industry show a wider margin of safety.

Is REPL undervalued or overvalued?

We do not publish a verdict on REPL yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.

What is the intrinsic value of REPL?

We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.